BHVN / Biohaven Drug Is a Long Shot, But Success Could Boost Shares

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year. more_horizontal

Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. more_horizontal

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases. more_horizontal

Biohaven released a new investor presentation that featured encouraging information about drug candidate BHV-1300. The experimental drug showed promis more_horizontal

The FDA refused to review Biohaven's filing for approval of troriluzole in treating an ultrarare disease. Biohaven still hopes to convince the agency more_horizontal

Wednesday, Biohaven held a research and development day presentation for investors. With the company making progress on several fronts, investors appe more_horizontal

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders. more_horizontal

Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either e more_horizontal